With respect to the combination of PD-1/CTLA-4 inhibitors, a meta-analysis demonstrated that the IO+chemotherapy (CT) regimen resulted in a significant increase of ORR, among single-agent IO, IO+CT, and combination of PD-1/CTLA-4 inhibitors (ComboIO), for the first-line treatment of patients with advanced NSCLC. This evidence concerns the gene CTLA4 and non-small cell lung carcinoma.